Important note

This AI stock analysis for Humana is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Humana - AI Stock Analysis

Analysis generated April 3, 2024

Humana Inc. is a leading health and well-being company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. The company serves millions of members across the United States and is well known for its Medicare Advantage and Prescription Drug Plans. By putting a strong emphasis on preventive care, personalized health plans, and innovative health technology solutions, Humana has established a significant footprint in the health insurance industry.

Fundamental Analysis

Considering Humana's financial performance, the last quarter showed a small revenue increase of 0.15% quarter-over-quarter to $26.5B, indicating consistent business performance. More impressive is the 17.93% year-over-year revenue growth showcasing significant expansion and market penetration. Net income, however, showed a significant decline of 165.02% compared to the previous quarter, with earnings slipping to $541M. Comparatively, net income plummeted by 3,506.67% from the same quarter in the previous year, raising major concerns about profitability and cost management. EBITDA fell to $258M representing a 78.84% decline quarter-over-quarter but offsets this drop with a substantial 369.09% increase year-over-year. The current P/E ratio of 17.57 suggests the stock is reasonably valued when compared to industry peers and does not exhibit signs of overvaluation or undervaluation.

Technical Analysis

The technical indicators for Humana show a worrying trend. The bearish stock momentum is evidenced by a declining Simple Moving Average, with the SMA10 falling to 339.08 from 343.27. The relative strength index (RSI) is at 49.1, which suggests a neutral momentum without clear indicators for immediate buy or sell-action. If the RSI were to trend lower, it could signal a potential strengthening of the bearish trend.

Alternative Data Analysis

Alternative data offers additional insights into Humana's performance. Job postings have been stable at 1,177 open positions, reflecting a steady organizational growth rate. Employee sentiment towards Humana's business outlook is neutral, which doesn't raise particular red flags but also does not highlight exceptional corporate health. Humana's digital footprint shows a 9% decrease in website visitors, totaling an estimated 6.4M, and an 8% decrease in daily mobile app downloads to 650, both indicating possible declines in customer acquisition efforts. Conversely, Humana's Instagram followers increased by 5% to 20,000, showing a glimmer of positive engagement, although Twitter followers remained flat at 44,000, suggesting a plateau in customer engagement on that platform.

Conclusion and Recommendation

In conclusion, Humana exhibits solid year-over-year revenue growth, but recent profitability concerns, a bearish technical trend, and mixed signals from alternative data sources generate caution. The overall recommendation would be to hold for existing investors, monitoring closely the company's cost management and profitability strategies in upcoming quarters. Potential investors should seek additional signs of a turnaround in net income and technical indicators before considering entry. Despite the mixed data, Humana's fundamental role in the growing healthcare sector and its pe ratio potential for long-term value creation should keep it on investors' watchlists.